• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aurinia Pharmaceuticals Inc

    5/16/25 5:01:56 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AUPH alert in real time by email
    S-8 1 auph-2025may16sx8.htm S-8 Document

    As filed with the U.S. Securities and Exchange Commission on May 16, 2025
    Registration No. 333- __________
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _____________________________________

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    _____________________________________
    Aurinia Pharmaceuticals Inc.
    (Exact name of registrant as specified in its charter)
    Alberta, Canada98-1231763
    (State or other jurisdiction of incorporation or organization)
    (IRS Employer Identification No.)

    #140, 14315 - 118 Avenue
    Edmonton, Alberta
    T5L 4S6
    (Address of principal executive offices) (Zip code)

    Aurinia Pharmaceuticals Inc. Amended and Restated Equity Incentive Plan
    (Full title of the plan)
    _____________________________________

    Stephen Robertson
    Executive Vice President, General Counsel,
    Chief Compliance Officer and Corporate Secretary
    Aurinia Pharmaceuticals Inc.
    #140, 14315 - 118 Avenue
    Edmonton, Alberta
    T5L 4S6
    (Name and address of agent for service)
    (250) 744-2487
    (Telephone number, including area code, of agent for service)

    Copies to:
    Raquel Fox
    Skadden, Arps, Slate, Meagher & Flom LLP
    1440 New York Avenue, NW
    Washington, DC 20005
    (202) 371-7000
    Michelle Wilkinson
    Borden Ladner Gervais LLP
    1200 Waterfront Centre
    P.O. Box 48600
    Vancouver, British Columbia V7X 1T2
    (604) 687-5744
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer þ    Accelerated filer    ☐
    Non-accelerated filer ☐    Smaller reporting company ☐
        Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE

    Aurinia Pharmaceuticals Inc. Amended and Restated Equity Incentive Plan
    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 6,000,000 common shares, no par value per share (the “Common Shares”) of Aurinia Pharmaceuticals Inc. (the “Registrant”), in connection with the Aurinia Pharmaceuticals Inc. Amended and Restated Equity Incentive Plan.
    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    Item 1.    Plan Information.*
    Item 2.    Registrant Information and Employee Plan Annual Information.*
    *The documents containing the information specified in “Item 1. Plan Information” and “Item 2. Registrant Information and Employee Plan Annual Information” of Form S-8 will be sent or given to participants in the Plans, as applicable, as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be, and are not, filed with the Commission either as part of this Registration Statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.





    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3.    Incorporation of Certain Documents by Reference.
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement as of their respective dates:
    1.the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Commission on February 27, 2025;
    2.the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 12, 2025;
    3.the Registrant’s Current Report on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed with the Commission on May 15, 2025; and
    4.the description of the Common Shares contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Commission on February 24, 2021, including any future amendment or report filed for the purpose of amending such description.
    In addition, all reports and documents filed by the Registrant under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities being offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in and to be part of this Registration Statement from the date of filing of each such document, provided that reports on Form 8-K shall be so deemed incorporated by reference only if and to the extent indicated in such reports.
    Unless expressly incorporated into this Registration Statement, a report furnished but not filed on Form 8-K under the Exchange Act shall not be incorporated by reference in to this Registration Statement.
    Item 4.    Description of Securities.
    Not applicable.
    Item 5.    Interests of Named Experts and Counsel.
    Not applicable.
    Item 6.    Indemnification of Directors and Officers.
    Under the Business Corporations Act (Alberta) (the “ABCA”), except in respect of an action by or on behalf of the Registrant or a Related Entity (as defined below) to procure a judgement in its favor, the Registrant may indemnify a present or former director or officer of the Registrant or a person who acts or acted at the Registrant’s request as a director or officer of another entity of which the Registrant is or was a shareholder or creditor (“Related Entity”), and the director’s or officer’s heirs and legal representatives against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the director or officer in respect of any civil, criminal, administrative, investigative or other action or proceeding (a “Proceeding”) in which the director or officer is involved by reason of being or having been a director or officer of the Registrant or Related Entity and provided that (i) such person acted honestly and in good faith with a view to the best interests of the Registrant and Related Entity, as applicable, and (ii) in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, had reasonable grounds for believing that such person’s conduct was lawful. The indemnification may be made in connection with a derivative action only with court approval.
    Any of the persons described in the first sentence of the foregoing paragraph are entitled to indemnification from the Registrant as a matter of right if the person seeking indemnity (a) was not judged by a court or competent authority to have committed any fault or omitted to do anything that the person ought to have done, and (b) fulfilled the conditions set forth in (i) and (ii) above.



    The Registrant may advance monies to any person described above for the costs, charges and expenses of a Proceeding. However, the person must repay the monies if the person does not fulfill the conditions set forth above.
    The foregoing description is qualified in its entirety by reference to the ABCA.
    The Registrant is a party to an indemnity agreement with each director and officer of the Registrant providing that if such director or officer is or was involved in any threatened, pending or completed Proceeding by reason of the fact that such director or officer is or was a director or officer of the Registrant or is or was serving at the request of the Registrant as a director or officer of another entity, including service with respect to employee benefit plans, whether the basis of such Proceeding is an alleged action in an official capacity while serving as a director or officer, such director or officer will be indemnified and held harmless by the Registrant to the fullest extent authorized by and in the manner set forth in the ABCA against all expense, liability and loss reasonably incurred or suffered by such director or officer in connection therewith. Under such indemnity agreements, the Registrant may indemnify any of its directors or officers in connection with a Proceeding (or part thereof) initiated by such director or officer only if such Proceeding (or part thereof) is authorized by the board of directors of the Registrant or if such Proceeding is a successful Proceeding, in whole or in part, by a director or officer for claims under an indemnity agreement.
    The ABCA provides that the Registrant may purchase and maintain insurance for the benefit of any persons described in the first sentence of the first paragraph of this section against any liability incurred by the person in the person’s capacity as a director or officer of the Registrant or Related Entity.
    The Registrant maintains directors’ and officers’ liability insurance. The policies insure (a) the directors and officers of the Registrant against losses arising from claims against them for certain of their actual or alleged wrongful acts (as defined within the insurance policy), (b) the Registrant for payments made pursuant to the Registrant’s indemnification of its directors and officers and (c) the Registrant when it is directly named in a securities claim. The policies provide a maximum coverage in any one policy year of $60 million in annual claims, $25 million of which is dedicated solely to the directors and officers of the Registrant for non-indemnifiable claims. A $3.5 million per claim deductible is applicable to indemnifiable claims and securities claims brought against the Registrant; no deductible shall apply to non-indemnifiable claims. The premiums for the policies were not allocated between directors and officers as separate groups.
    By-law No. 2 of the Registrant provides that, except as otherwise provided in the ABCA, no director or officer will be liable for:
    a)the acts, receipts, neglects or defaults of any other director, officer or employee, or for joining in a receipt or act for conformity;
    b)any loss, damage or expense happening to the Registrant through the insufficiency or deficiency of title to any property acquired by, for, or on behalf of the Registrant;
    c)
    the insufficiency or deficiency of any security in or upon which monies of or belonging to the Registrant shall be placed or invested;
    d)
    any loss or damage arising from the bankruptcy, insolvency or tortious acts of any person, firm or corporation, including any person, firm or corporation with whom any monies, securities or other effects of the Registrant is lodged or deposited;
    e)any loss, conversion, misapplication or misappropriation of or any damage resulting from any dealings with any monies, securities or other assets of or belonging to the Registrant; or
    f)
    any other loss, damage, or misfortune which may happen in the execution of the duties of a director’s or officer’s respective office or trust or in relation thereto;
    unless the foregoing shall happen by or through such director’s or officer’s failure to exercise the powers and to discharge the duties of their office honestly and in good faith with a view to the best interests of the Registrant and through a failure to exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.
    Item 7.    Exemption from Registration Claimed.
    Not applicable.




    Item 8.    Exhibits.
    Incorporated by Reference
    Exhibit NumberDescriptionFormFile NumberExhibitFile Date
    4.1
    Articles of Amalgamation of Aurinia Pharmaceuticals Inc., as amended, as currently in effect.
    10-K001-364213.1February 24, 2021
    4.2
    Amended and Restated By-Law No. 2, as amended and currently in effect
    8-K001-364213.1May 15, 2025
    4.3
    Form of Common Shares Certificate of Aurinia Pharmaceuticals Inc.
    10-K001-364214.1February 24, 2021
    5.1*
    Opinion of Borden Ladner Gervais LLP
    10.1
    Aurinia Pharmaceuticals Inc. Equity Incentive Plan, as amended and restated as of May 15, 2025
    8-K
    001-36421
    99.1May 15, 2025
    23.1*
    Consent of Borden Ladner Gervais LLP (included in Exhibit 5.1)
    23.2*
    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
    24.1*
    Power of Attorney (included on the signature page of this Form S-8).
    107*
    Filing Fee Table
            
    *Filed herewith






    Item 9.    Undertakings.
    (a) The undersigned Registrant hereby undertakes,
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in this Registration Statement;
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Rockville, State of Maryland, on May 16, 2025.


    AURINIA PHARMACEUTICALS INC.
    By: /s/ Peter S. Greenleaf    
        Peter S. Greenleaf
        President and Chief Executive Officer




    POWER OF ATTORNEY
    Each person whose signature appears below constitutes and appoints Peter S. Greenleaf and Joseph M. Miller, and each of them, any of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this Registration Statement and registration statements filed pursuant to Rule 429 under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting alone, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
    SignatureTitleDate
    /s/ Peter S. GreenleafPresident, Chief Executive Officer May 16, 2025
    Peter S. Greenleaf(Principal Executive Officer)
    /s/ Joseph M. MillerChief Financial OfficerMay 16, 2025
    Joseph M. Miller(Principal Financial Officer and
    Principal Accounting Officer)
    /s/ Kevin TangChair of the BoardMay 16, 2025
    Kevin Tang
    /s/ Jeffrey A. BaileyDirectorMay 16, 2025
    Jeffrey A. Bailey
    /s/ Kathy L. GoetzDirectorMay 16, 2025
    Kathy L. Goetz
    /s/ Craig JohnsonDirectorMay 16, 2025
    Craig Johnson
    /s/ Tina S. NovaDirectorMay 16, 2025
    Tina S. Nova



    Get the next $AUPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AUPH

    DatePrice TargetRatingAnalyst
    11/4/2022Outperform → Perform
    Oppenheimer
    5/5/2022$34.00 → $25.00Overweight
    Cantor Fitzgerald
    3/8/2022$30.00 → $22.00Outperform
    SVB Leerink
    3/1/2022$31.00 → $27.00Outperform
    RBC Capital
    2/23/2022$34.00 → $31.00Outperform
    RBC Capital
    12/10/2021$33.00 → $31.00Perform → Outperform
    Oppenheimer
    11/4/2021$32.00 → $33.00Perform
    Oppenheimer
    11/4/2021$35.00 → $40.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AUPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Total Revenue: For the three months ended March 31, 2025, total revenue was $62.5 million, up 24% from $50.3 million in the same period of 2024. Net Product Sales: For the three months ended March 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $60.0 million, up 25% from $48.1 million in the same period of 2024. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2025, license, collaboration and royalty

      5/12/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025. Aurinia's management team will host a conference call and webcast at 8:30 AM ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medi

      5/5/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

      Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH) today announced that leading independent proxy advisor Glass, Lewis & Co. LLC ("Glass Lewis") has recommended that Aurinia shareholders vote FOR all proposals put forth by the Board of Directors (the "Board") at the Company's 2025 Annual General Meeting (the "Meeting") on Thursday, May 15, 2025, at 12:00 p.m., Eastern Time. Glass Lewis supports all of the proposals in the Company's proxy statement and management information circular (the "Proxy Statement/Circular"), including approving the six director nominees, the proposed auditor, the non-binding advisory vote on the Company's approach to executive compensation, and

      4/30/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    SEC Filings

    See more
    • SEC Form S-8 filed by Aurinia Pharmaceuticals Inc

      S-8 - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/16/25 5:01:56 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/15/25 4:06:13 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aurinia Pharmaceuticals Inc

      10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

      5/12/25 6:05:39 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aurinia Pharmaceuticals Inc

      SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

      11/14/24 4:47:34 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Aurinia Pharmaceuticals Inc

      SC 13D - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

      9/12/24 4:10:26 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aurinia Pharmaceuticals Inc (Amendment)

      SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

      3/20/24 5:23:55 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tang Kevin bought $12,713,126 worth of shares (1,600,000 units at $7.95) (SEC Form 4)

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      3/4/25 5:03:02 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tang Kevin bought $10,822,000 worth of shares (1,200,000 units at $9.02) (SEC Form 4)

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      12/9/24 4:52:50 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Financials

    Live finance-specific insights

    See more
    • Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Total Revenue: For the three months ended March 31, 2025, total revenue was $62.5 million, up 24% from $50.3 million in the same period of 2024. Net Product Sales: For the three months ended March 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $60.0 million, up 25% from $48.1 million in the same period of 2024. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2025, license, collaboration and royalty

      5/12/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025. Aurinia's management team will host a conference call and webcast at 8:30 AM ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medi

      5/5/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress. Fourth Quarter 2024 Financial Results Total Revenue: For the three months ended December 31, 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023. – Net Product Sales: For the three months ended December 31, 2024, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $57.6 million, up 36% from $42.3 million in the same period of 2023. – License, Collaboration and Royalty Revenue

      2/27/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Nova Tina Susan

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      5/16/25 5:06:05 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Johnson Craig A

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      5/16/25 5:05:19 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Goetz Kathleen

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      5/16/25 5:04:45 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for LUPKYNIS

      Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

      1/25/21 11:31:10 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently serves as a director of Heron Therapeutics, Inc. His biography can be found here. The Company also announced that Dr. Robert

      11/7/24 6:10:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Announces 2024 Annual General Meeting Results

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committ

      6/14/24 12:16:00 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors ("the Board") has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR. "We are appreciative of MKT's constructive collaboration efforts. Dr. Foster brings talents which can help strengthen the Board even further

      9/21/23 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AUPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aurinia Pharma downgraded by Oppenheimer

      Oppenheimer downgraded Aurinia Pharma from Outperform to Perform

      11/4/22 7:15:31 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Aurinia Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Aurinia Pharma with a rating of Overweight and set a new price target of $25.00 from $34.00 previously

      5/5/22 9:08:41 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Aurinia Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $22.00 from $30.00 previously

      3/8/22 4:46:01 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care